These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
437 related articles for article (PubMed ID: 20144472)
1. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. Cox L; Larenas-Linnemann D; Lockey RF; Passalacqua G J Allergy Clin Immunol; 2010 Mar; 125(3):569-74, 574.e1-574.e7. PubMed ID: 20144472 [TBL] [Abstract][Full Text] [Related]
2. Systemic reactions to subcutaneous allergen immunotherapy and the response to epinephrine. Phillips JF; Lockey RF; Fox RW; Ledford DK; Glaum MC Allergy Asthma Proc; 2011; 32(4):288-94. PubMed ID: 21781404 [TBL] [Abstract][Full Text] [Related]
3. [Analysis of adverse reactions induced by subcutaneous immunotherapy against dust mite allergy in 234 cases with allergic rhinitis and asthma]. Li MR; Wang XN; Jiang HD; Wang QY; Li YC; Lin J; Jin K; Zhang HL; Li CC Zhonghua Er Ke Za Zhi; 2012 Oct; 50(10):726-31. PubMed ID: 23302557 [TBL] [Abstract][Full Text] [Related]
4. Oral immunotherapy for peanut allergy: multipractice experience with epinephrine-treated reactions. Wasserman RL; Factor JM; Baker JW; Mansfield LE; Katz Y; Hague AR; Paul MM; Sugerman RW; Lee JO; Lester MR; Mendelson LM; Nacshon L; Levy MB; Goldberg MR; Elizur A J Allergy Clin Immunol Pract; 2014; 2(1):91-6. PubMed ID: 24565775 [TBL] [Abstract][Full Text] [Related]
5. Risk of systemic allergic reactions to allergen immunotherapy in a pediatric allergy clinic in Turkey. Bahceci Erdem S; Nacaroglu HT; Karaman S; Unsal Karkıner CS; Gunay I; Dogan D; Asilsoy S; Altınoz S; Can D Int J Pediatr Otorhinolaryngol; 2016 May; 84():55-60. PubMed ID: 27063754 [TBL] [Abstract][Full Text] [Related]
6. AAAAI/ACAAI Subcutaneous Immunotherapy Surveillance Study (2013-2017): Fatalities, Infections, Delayed Reactions, and Use of Epinephrine Autoinjectors. Epstein TG; Liss GM; Berendts KM; Bernstein DI J Allergy Clin Immunol Pract; 2019; 7(6):1996-2003.e1. PubMed ID: 30776526 [TBL] [Abstract][Full Text] [Related]
7. Immediate and delayed-onset systemic reactions after subcutaneous immunotherapy injections: ACAAI/AAAAI surveillance study of subcutaneous immunotherapy: year 2. Epstein TG; Liss GM; Murphy-Berendts K; Bernstein DI Ann Allergy Asthma Immunol; 2011 Nov; 107(5):426-431.e1. PubMed ID: 22018614 [TBL] [Abstract][Full Text] [Related]
8. Should Epinephrine Autoinjectors Be Prescribed to All Patients on Subcutaneous Immunotherapy? Fitzhugh DJ; Bernstein DI J Allergy Clin Immunol Pract; 2016; 4(5):862-7. PubMed ID: 27209596 [TBL] [Abstract][Full Text] [Related]
9. Systemic Allergic Reactions and Anaphylaxis Associated with Allergen Immunotherapy. Dhamija Y; Epstein TEG; Bernstein DI Immunol Allergy Clin North Am; 2022 Feb; 42(1):105-119. PubMed ID: 34823741 [TBL] [Abstract][Full Text] [Related]
10. AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactions. Epstein TG; Liss GM; Murphy-Berendts K; Bernstein DI J Allergy Clin Immunol Pract; 2014; 2(2):161-7. PubMed ID: 24607043 [TBL] [Abstract][Full Text] [Related]
11. Incidence and characteristics of biphasic reactions after allergen immunotherapy. Scranton SE; Gonzalez EG; Waibel KH J Allergy Clin Immunol; 2009 Feb; 123(2):493-8. PubMed ID: 19064282 [TBL] [Abstract][Full Text] [Related]
12. Safety of subcutaneous immunotherapy with inhalant allergen extracts: a single-center 30-year experience from Turkey. Kartal O; Gulec M; Caliskaner Z; Musabak U; Sener O Immunopharmacol Immunotoxicol; 2015 Jun; 37(3):280-6. PubMed ID: 25858053 [TBL] [Abstract][Full Text] [Related]
13. Safety of sublingual grass pollen immunotherapy after anaphylaxis. Nichani JR; de Carpentier J J Laryngol Otol; 2009 Jun; 123(6):683-4. PubMed ID: 18501039 [TBL] [Abstract][Full Text] [Related]
14. Safety of allergen immunotherapy in North America from 2008-2017: Lessons learned from the ACAAI/AAAAI National Surveillance Study of adverse reactions to allergen immunotherapy. Bernstein DI; Epstein TEG Allergy Asthma Proc; 2020 Mar; 41(2):108-111. PubMed ID: 32122446 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapy safety: what have we learned from surveillance surveys? Kannan JA; Epstein TG Curr Allergy Asthma Rep; 2013 Aug; 13(4):381-8. PubMed ID: 23636820 [TBL] [Abstract][Full Text] [Related]
16. Is faster safer? Cluster versus short conventional subcutaneous allergen immunotherapy. Quiralte J; Justicia JL; Cardona V; Dávila I; Moreno E; Ruiz B; García MA Immunotherapy; 2013 Dec; 5(12):1295-303. PubMed ID: 24283840 [TBL] [Abstract][Full Text] [Related]
17. The safety of self-administered allergen immunotherapy during the buildup and maintenance phases. Schaffer FM; Naples AR; Ebeling M; Hulsey TC; Garner LM Int Forum Allergy Rhinol; 2015 Feb; 5(2):149-56. PubMed ID: 25476041 [TBL] [Abstract][Full Text] [Related]
18. [New administration routes for immunotherapy]. Martorell Aragonés A Allergol Immunopathol (Madr); 2000; 28(3):93-102. PubMed ID: 10867377 [TBL] [Abstract][Full Text] [Related]
19. Imported fire ant field reaction and immunotherapy safety characteristics: the IFACS study. La Shell MS; Calabria CW; Quinn JM J Allergy Clin Immunol; 2010 Jun; 125(6):1294-9. PubMed ID: 20451988 [TBL] [Abstract][Full Text] [Related]
20. European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real-life clinical assessment. Calderón MA; Vidal C; Rodríguez Del Río P; Just J; Pfaar O; Tabar AI; Sánchez-Machín I; Bubel P; Borja J; Eberle P; Reiber R; Bouvier M; Lepelliez A; Klimek L; Demoly P; Allergy; 2017 Mar; 72(3):462-472. PubMed ID: 27718250 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]